Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics

Pfizer

CRISPR Therapeutics could soon win approval for its first product. Novocure has big news on the way in a matter of days.

3 No-Brainer Stocks to Buy for Under $100 Right Now

The case against Novocure centers on its declining sales and uncertainty about expanding into new markets. The case for Novocure focuses on the company's huge prospects if its late-stage clinical studies go well.

Should You Buy Novocure Stock Right Now?

NovoCure Limited (NASDAQ:NVCR ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Frank Leonard - President, CNS Cancers U.S. Conference Call Participants Greg Fraser - Truist Securities Emily Bodnar - H.C. Wainwright Na Sun - JPMorgan Chase & Co. Operator Good day, and thank you for standing by.

NovoCure Limited (NVCR) Q1 2023 Earnings Call Transcript

NovoCure (NVCR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.04 per share a year ago.

NovoCure (NVCR) Reports Q1 Loss, Lags Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports First Quarter 2023 Financial Results.

Novocure Reports First Quarter 2023 Financial Results

Senseonics Holdings

Veeva Systems

In discussing healthcare tech stocks, it pays to understand what healthcare technology is broadly. Healthcare technology, also known as HealthTech, refers to any technology developed to improve the healthcare system.

The 3 Most Promising Healthcare Tech Stocks for April 2023

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6. The LUNAR study is a phase 3, open-label, randomized study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with standard therapies.

Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced 27 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida.

Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the first quarter 2023 on May 4, 2023, before the U.S. financial markets open.

Novocure to Report First Quarter 2023 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure's Board of Directors. “We look forward to welcoming Ms. Stafford to our board of directors,” said William Doyle, Novocure's Executive Chairman. “Her broad expertise in finance in the life sciences sector and experience with a leading funder of innovation across the biopharmaceutical industry will be valuable as our global organization prepares for future growth.” Ms.

Kristin Stafford Joins Novocure Board of Directors

NovoCure has seen strong growth over the past decade but is unable to post profits with large sums invested into the pipeline. After softer sales momentum, pipeline conversion to other cancer types is necessary to drive appeal.

NovoCure: Pipeline Conversion Is Key

NovoCure focuses on promoting Optune and Optune Lua, FDA-approved devices utilizing Tumor Treating Fields (TTFields) technology to target and destroy cancer cells. The LUNAR study in non-small cell lung cancer (NSCLC) met its primary endpoint, showing significant improvement in overall survival when using TTFields with standard therapies. Details are expected in June.

Exploring The Potential Of NovoCure's TTFields In Non-Small Cell Lung Cancer

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.

Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Zai Lab Ltd.

The bear market has been brutal to small and unprofitable biopharma stocks. Zai Lab plans to commercialize a baffling number of its programs, and soon.

2 Stocks That Could Rebound and Rise 30% or More in 2023

Axon Enterprise

The central bank's plan to aggressively hike interest rates might trigger a sharp correction in U.S. stock markets. Axon Enterprise and NovoCure are two companies with economically insensitive business models, making them ideal safe-haven plays.

2 Best Defensive Stocks to Buy in March

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering Optune on the List of Reimbursable Products and Services (LPPR) provided for in Article L165-1 of the Social Security Code was published in the Official Journal on February 28, 2023 and will become effective March 15, 2023.

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced that the final patient has enrolled in the pivotal METIS study.

Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Investors were looking for a stronger Q4 from the cancer company.

Why NovoCure Stock Is Falling Today

Novocure Limited (NASDAQ:NVCR ) Q4 2022 Results Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Pritesh Shah - Chief Growth Officer Conference Call Participants Na Sun - JPMorgan Chase & Co. Jason Wittes - Loop Capital Lei Huang - Wells Fargo Jason Bednar - Piper Sandler Greg Fraser - Truist Securities Vijay Kumar - Evercore ISI Emily Bodnar - H.C. Wainwright Ingrid Goldberg Good morning, everyone, and thank you for joining us to review Novocure's Fourth Quarter and Full Year 2022 Performance.

Novocure Limited (NVCR) Q4 2022 Earnings Call Transcript

NovoCure (NVCR) delivered earnings and revenue surprises of -12.50% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Allyson J. Ocean, M.D., has been elected to Novocure's Board of Directors. Dr. Ocean brings decades of experience in oncology to Novocure.

Allyson J. Ocean, M.D., Joins Novocure Board of Directors

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for

There was good news from the laboratory on Hump Day.

Why Novocure Stock Was so Healthy Today

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced that the final patient has been enrolled in the pivotal PANOVA-3 study.

News for Novocure Stock (NVCR)